Noa Biran

1.7k total citations
89 papers, 427 citations indexed

About

Noa Biran is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Noa Biran has authored 89 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 77 papers in Hematology, 52 papers in Molecular Biology and 43 papers in Oncology. Recurrent topics in Noa Biran's work include Multiple Myeloma Research and Treatments (74 papers), Protein Degradation and Inhibitors (39 papers) and Peptidase Inhibition and Analysis (15 papers). Noa Biran is often cited by papers focused on Multiple Myeloma Research and Treatments (74 papers), Protein Degradation and Inhibitors (39 papers) and Peptidase Inhibition and Analysis (15 papers). Noa Biran collaborates with scholars based in United States, Canada and France. Noa Biran's co-authors include Ajai Chari, Sundar Jagannath, David S. Siegel, David H. Vesole, Hearn Jay Cho, Joshua Richter, Scott Ely, Emilia Bagiella, Jyoti Malhotra and Andrew L. Pecora and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Noa Biran

77 papers receiving 420 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Noa Biran United States	12	322	256	226	41	38	89	427
Zhao Yang United States	10	233 0.7×	177 0.7×	199 0.9×	57 1.4×	73 1.9×	21	408
Alissa Visram Canada	12	244 0.8×	158 0.6×	198 0.9×	76 1.9×	27 0.7×	57	403
Raid G. Ossi United States	3	499 1.5×	329 1.3×	268 1.2×	37 0.9×	13 0.3×	4	545
Anjla Sood United States	7	346 1.1×	385 1.5×	181 0.8×	26 0.6×	11 0.3×	10	476
Jainulabdeen J. Ifthikharuddin United States	6	419 1.3×	279 1.1×	275 1.2×	69 1.7×	57 1.5×	12	482
Maria Krevvata United States	8	422 1.3×	288 1.1×	263 1.2×	72 1.8×	62 1.6×	23	479
Even H. Rustad United States	9	214 0.7×	159 0.6×	147 0.7×	67 1.6×	18 0.5×	13	306
Carmen Martínez‐Chamorro Spain	9	341 1.1×	128 0.5×	173 0.8×	38 0.9×	19 0.5×	15	383
Mihaela Popa McKiver United States	6	419 1.3×	320 1.3×	399 1.8×	122 3.0×	46 1.2×	12	568
Loredana Santo United States	9	456 1.4×	383 1.5×	326 1.4×	83 2.0×	20 0.5×	23	633

Countries citing papers authored by Noa Biran

Since Specialization

Citations

This map shows the geographic impact of Noa Biran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noa Biran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noa Biran more than expected).

Fields of papers citing papers by Noa Biran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noa Biran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noa Biran. The network helps show where Noa Biran may publish in the future.

Co-authorship network of co-authors of Noa Biran

This figure shows the co-authorship network connecting the top 25 collaborators of Noa Biran. A scholar is included among the top collaborators of Noa Biran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noa Biran. Noa Biran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Amoozgar, Behzad, David H. Vesole, David S. Siegel, et al.. (2025). Impact of Extramedullary Disease on Survival Outcomes in Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel and Idecabtagene Vicleucel: A Comparative Analysis. Transplantation and Cellular Therapy. 31(2). S237–S238. 1 indexed citations

Landgren, Ola, Noa Biran, Elizabeth O’Donnell, et al.. (2025). Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma. HemaSphere. 9(7). e70178–e70178.

Vesole, David H., Thomas G Martin, Suzanne Trudel, et al.. (2024). Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 1982–1982. 1 indexed citations

Ye, Jing Christine, Noa Biran, Sandhya Nair, et al.. (2024). P-099 Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 24. S99–S100. 1 indexed citations

Aleman, Adolfo, et al.. (2024). Mortality trends (1999-2022) in patients with multiple myeloma with pneumonia, influenza, and COVID-19.. Journal of Clinical Oncology. 42(16_suppl). 7553–7553. 1 indexed citations

Baljević, Muhamed, Nizar J. Bahlis, Rami Kotb, et al.. (2024). Efficacy and Safety of Selinexor, Pomalidomide, and Dexamethasone (SPd) for Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 144(Supplement 1). 1996–1996. 1 indexed citations

Biran, Noa, David H. Vesole, Andrew J. Belli, et al.. (2024). Effect of maintenance therapy (MT) on real-world outcomes (RWO) of patients (pts) with newly diagnosed multiple myeloma (NDMM) post stem cell transplant (SCT).. Journal of Clinical Oncology. 42(16_suppl). 7562–7562.

Richard, Shambavi, Alexander M. Lesokhin, Barry Paul, et al.. (2024). Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial. Nature Cancer. 5(10). 1459–1464. 8 indexed citations

Biran, Noa, Hyung C. Suh, Christina Cho, et al.. (2023). Comparison of Fludarabine/Cyclophosphamide Vs Bendamustine As Lymphodepleting Regimen for CAR-T: A Safety and Efficacy Analysis in Patients with Relapsed/ Refractory Multiple Myeloma. Blood. 142(Supplement 1). 6903–6903. 1 indexed citations

10.

Reich‐Slotky, Ronit, Pashna N. Munshi, Noa Biran, et al.. (2022). Sustained Hematopoietic Engraftment Potential after Prolonged Storage of Cryopreserved Hematopoietic Stem Cells Used in Salvage Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. 28(6). 306.e1–306.e7. 1 indexed citations

11.

Biran, Noa, Wanting Zhai, Roxanne E. Jensen, et al.. (2021). Patient‐reported outcomes following autologous stem cell transplant for patients with multiple myeloma. SHILAP Revista de lepidopterología. 2(3). 488–492. 4 indexed citations

12.

Leng, Siyang, Erin Moshier, Douglas Tremblay, et al.. (2020). Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies. Clinical Lymphoma Myeloma & Leukemia. 20(10). e734–e751. 2 indexed citations

13.

Biran, Noa, et al.. (2020). Adaptation and Evaluation of a Symptom-Monitoring Digital Health Intervention for Patients With Relapsed and Refractory Multiple Myeloma: Pilot Mixed-Methods Implementation Study. JMIR Formative Research. 4(11). e18982–e18982. 12 indexed citations

14.

Skarbnik, Alan P, Michèle L. Donato, Rena Feinman, et al.. (2020). Safety and Efficacy of Consolidation Therapy with Ipilimumab Plus Nivolumab after Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. 27(5). 391–403. 8 indexed citations

15.

Richter, Joshua, Larysa Sanchez, Noa Biran, et al.. (2020). Prevalence and Survival Impact of Self-Reported Symptom and Psychological Distress Among Patients With Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 21(3). e284–e289. 15 indexed citations

16.

Nikolaenko, Liana, Saurabh Chhabra, Noa Biran, et al.. (2020). Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation. Clinical Lymphoma Myeloma & Leukemia. 20(6). 407–414. 11 indexed citations

17.

Biran, Noa, Tracy Andrews, Rena Feinman, et al.. (2017). A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone As Post Autologous Stem Cell Transplant Consolidation in Patients with High-Risk Multiple Myeloma. Blood. 130. 1831–1831. 8 indexed citations

18.

Biran, Noa, Scott Ely, & Ajai Chari. (2014). Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques. Current Hematologic Malignancy Reports. 9(4). 368–378. 17 indexed citations

19.

Adelson, Kerin B., Doris Germain, George Raptis, & Noa Biran. (2011). Hormonal Modulation in the Treatment of Breast Cancer. Endocrinology and Metabolism Clinics of North America. 40(3). 519–532. 6 indexed citations

20.

Tanna, Neil, Diego Preciado, & Noa Biran. (2009). The Otolaryngologic Features of Sanjad-Sakati Syndrome. Archives of Otolaryngology - Head and Neck Surgery. 135(7). 714–714. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact